Study on the Mechanism of Exosome-Mediated Transmission of IFN-α Anti-HBV Effects

Abstract

Interferon-alpha (IFN-α) plays a central role in hepatitis B virus (HBV) treatment, but its mechanism of action remains incompletely understood. The latest research by Yuan Zhenghong's team at Fudan University reveals that macrophage-derived exosomes can transmit IFN-α-induced antiviral effects to HBV-infected hepatocytes by mimicking the molecular mechanisms of viral invasion. This process involves TIM-1 receptor-mediated endocytosis, clathrin-dependent pathways, and atypical macropinocytosis, relying on endosomal membrane fusion for cargo release. This mechanistic study provides a theoretical basis for developing exosome-based antiviral delivery systems. In this context, Biotinylated IFN-alpha/beta R1 His&Avi Tag protein serves as a critical research tool for IFN receptor signaling studies and exosome functional analysis.

I. Research Background and Significance

Hepatitis B virus (HBV) infection is a major cause of chronic hepatitis, cirrhosis, and liver cancer. IFN-α, as a first-line clinical anti-HBV drug, exhibits both direct antiviral and immunomodulatory functions. Previous studies have shown that non-parenchymal liver cells can transmit IFN-α-induced antiviral effects via exosomes, but the specific entry and release mechanisms remain unclear.

II. Molecular Mechanisms of Exosome Entry into Hepatocytes

1. Receptor-Mediated Recognition
Macrophage exosomes expose phosphatidylserine on their surface, binding to the viral receptor TIM-1 on hepatocytes via an "apoptotic mimicry" mechanism. Inhibiting TIM-1 expression significantly blocks exosome entry and antiviral effect transmission.

2. Endocytic Pathways
- Clathrin-Mediated Endocytosis (CME): Chlorpromazine treatment or knockdown of clathrin heavy chain inhibits exosome uptake;
- Atypical Macropinocytosis: Exosomes stimulate fluid-phase endocytosis, which depends on EIPA-sensitive pathways but is independent of Rac1 and Cdc42 signaling.

III. Mechanisms of Exosomal Endosomal Escape and Cargo Release

After endocytosis, exosomes undergo membrane fusion with late endosomes and multivesicular bodies, relying on LBPA-mediated endosomal penetration to escape lysosomal degradation and achieve cytoplasmic release of antiviral effectors. Blocking LBPA inhibits membrane fusion and promotes exosome cargo transport to lysosomes.

IV. Application Value of Biotinylated IFN-alpha/beta R1 His&Avi Tag Protein in Mechanistic Studies

This recombinant protein, constructed by fusing the extracellular domain of IFN-α/β receptor 1 (IFNAR1) with His and Avi tags and modified by biotinylation, has the following applications:

1. Receptor Binding and Endocytosis Studies
Can be used to analyze IFNAR1 expression and distribution on hepatocyte and exosome surfaces, exploring its role in endocytic pathways.

2. Signaling Pathway Mechanism Analysis
As a decoy receptor or detection probe, it helps elucidate the regulatory network of IFN-α signaling in exosome-mediated antiviral effect transmission.

3. Exosome Functional Labeling and Tracking
Combined with streptavidin-biotin systems, enables efficient labeling, capture, and imaging of exosomes and their cargo, advancing exosome-based drug carrier development.

4. Antiviral Drug Screening Platforms
High-throughput binding or blocking assays based on this protein can screen compounds or antibodies that enhance IFN-α effects or improve exosome delivery efficiency.

V. Suppliers of Biotinylated IFN-alpha/beta R1 His&Avi Tag Protein

Nanjing U-Protein自主研发的 Biotinylated IFN-alpha/beta R1 His&Avi Tag Protein, Human (Catalog No.: UA011308) is a high-purity, high-activity recombinant fusion protein based on the extracellular domain of human interferon-α/β receptor 1 (IFNAR1). This product is engineered to fuse the IFNAR1 extracellular domain with His and AviTag sequences, followed by site-specific biotinylation in vitro. It combines excellent ligand-binding activity, high detection sensitivity, and outstanding batch-to-batch consistency, making it an essential tool for studying type I interferon signaling, antiviral immunity, autoimmune diseases, and drug screening.

Nanjing U-Protein is committed to providing high-performance, high-quality recombinant protein tools for immunology research, antiviral drug development, and biotherapy. For detailed technical parameters, binding activity data, or application inquiries regarding Biotinylated IFN-alpha/beta R1 His&Avi Tag Protein, Human (Catalog No.: UA011308), please contact us anytime.